{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:05:56Z","timestamp":1789707956552,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Medical Research Project of Chengdu Health Commission","award":["2022101"],"award-info":[{"award-number":["2022101"]}]},{"name":"the Medical Research Project of Chengdu Health Commission","award":["2023038"],"award-info":[{"award-number":["2023038"]}]},{"name":"the Medical Research Project of Chengdu Health Commission","award":["2023560"],"award-info":[{"award-number":["2023560"]}]},{"name":"the Medical Research Project of Chengdu Health Commission","award":["2024114"],"award-info":[{"award-number":["2024114"]}]},{"name":"the Medical Research Project of Chengdu Health Commission","award":["2024194"],"award-info":[{"award-number":["2024194"]}]},{"name":"the Medical Research Project of Chengdu Health Commission","award":["2025358"],"award-info":[{"award-number":["2025358"]}]},{"name":"Key Research and the Science and Technology Department of Sichuan Province","award":["2023YFS0220"],"award-info":[{"award-number":["2023YFS0220"]}]},{"name":"the Medical Research Program of Sichuan Province","award":["grant number S22042"],"award-info":[{"award-number":["grant number S22042"]}]},{"name":"The Technology Innovation Research and Development project of Chengdu Science and Technology Bureau","award":["2022-YF05-02139-SN"],"award-info":[{"award-number":["2022-YF05-02139-SN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22780-y","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:49:07Z","timestamp":1762350547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Liping","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanlin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"22780_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2024 [R] (WHO, 2024)."},{"key":"22780_CR2","unstructured":"World Health Organization. Framework for Collaborative Action on Tuberculosis and Comorbidities (World Health Organization, 2022)."},{"key":"22780_CR3","doi-asserted-by":"publisher","first-page":"101316","DOI":"10.1016\/j.eclinm.2022.101316","volume":"45","author":"BR Adegbite","year":"2022","unstructured":"Adegbite, B. R. et al. Non-communicable disease co-morbidity and associated factors in tuberculosis patients: A cross-sectional study in Gabon. EClinicalMedicine 45, 101316. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101316 (2022).","journal-title":"EClinicalMedicine"},{"issue":"5","key":"22780_CR4","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.3346\/jkms.2023.38.e33","volume":"38","author":"H Choi","year":"2023","unstructured":"Choi, H. et al. Nationwide treatment outcomes of patients with multidrug\/rifampin-resistant tuberculosis in Korea, 2011\u20132017: A retrospective cohort study (Korean TB-POST). J. Korean Med. Sci. 38(5), e33. https:\/\/doi.org\/10.3346\/jkms.2023.38.e33 (2023).","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"22780_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12879-023-08765-0","volume":"23","author":"G Xu","year":"2023","unstructured":"Xu, G., Hu, X., Lian, Y. & Li, X. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: A systematic review and meta-analysis. BMC Infect. Dis. 23 (1), 813. https:\/\/doi.org\/10.1186\/s12879-023-08765-0 (2023).","journal-title":"BMC Infect. Dis."},{"key":"22780_CR6","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.jctube.2023.100398","volume":"33","author":"GK Getahun","year":"2023","unstructured":"Getahun, G. K. et al. Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in addis Ababa, Ethiopia: A retrospective follow-up study. J. Clin. Tuberc Other Mycobact. Dis. 33, 100398 (2023).","journal-title":"J. Clin. Tuberc Other Mycobact. Dis."},{"key":"22780_CR7","doi-asserted-by":"publisher","unstructured":"Chung, C. et al. Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney\/liver disease. Eur. Respir. J. 60(2), 2200930. https:\/\/doi.org\/10.1183\/13993003.00930-2022 (2022).","DOI":"10.1183\/13993003.00930-2022"},{"key":"22780_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2334-14-5","volume":"14","author":"CH Lin","year":"2014","unstructured":"Lin, C. H. et al. Tuberculosis mortality: Patient characteristics and causes. BMC Infect. Dis. 14, 5. https:\/\/doi.org\/10.1186\/1471-2334-14-5 (2014).","journal-title":"BMC Infect. Dis."},{"issue":"12","key":"22780_CR9","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/pathogens12121394","volume":"12","author":"A Starshinova","year":"2023","unstructured":"Starshinova, A. et al. Assessment of comorbidity in patients with drug-resistant tuberculosis. Pathogens 12(12), 1394. https:\/\/doi.org\/10.3390\/pathogens12121394 (2023).","journal-title":"Pathogens"},{"key":"22780_CR10","doi-asserted-by":"publisher","first-page":"1134938","DOI":"10.3389\/fpubh.2023.1134938","volume":"11","author":"J Lecai","year":"2023","unstructured":"Lecai, J. et al. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: A retrospective cohort study. Front. Public. Health 11, 1134938. https:\/\/doi.org\/10.3389\/fpubh.2023.1134938 (2023).","journal-title":"Front. Public. Health"},{"issue":"1","key":"22780_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12879-025-10802-z","volume":"25","author":"X Feng","year":"2025","unstructured":"Feng, X. et al. Risk factors for poor outcomes in patients with drug-resistant tuberculosis: A 6-year multicenter prospective study in Zhejiang, China. BMC Infect. Dis. 25(1), 422. https:\/\/doi.org\/10.1186\/s12879-025-10802-z (2025).","journal-title":"BMC Infect. Dis."},{"key":"22780_CR12","unstructured":"World Health Organization. WHO Consolidated Guidelines on tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 Update (World Health Organization, 2022)."},{"key":"22780_CR13","unstructured":"World Health Organization. Meeting Report of the WHO Expert Consultation on drug-resistant Tuberculosis Treatment Outcome definitions, 17\u201319 November 2020 (World Health Organization, 2021). Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"6","key":"22780_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000348374","volume":"86","author":"YA Kang","year":"2013","unstructured":"Kang, Y. A. et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration 86(6), 472\u2013478. https:\/\/doi.org\/10.1159\/000348374 (2013).","journal-title":"Respiration"},{"issue":"8","key":"22780_CR15","doi-asserted-by":"publisher","first-page":"CD016013","DOI":"10.1002\/14651858.CD016013.pub2","volume":"8","author":"JV Franco","year":"2024","unstructured":"Franco, J. V. et al. Diabetes as a risk factor for tuberculosis disease. Cochrane Database Syst. Rev. 8(8), CD016013. https:\/\/doi.org\/10.1002\/14651858.CD016013.pub2 (2024).","journal-title":"Cochrane Database Syst. Rev."},{"key":"22780_CR16","doi-asserted-by":"publisher","first-page":"1244450","DOI":"10.3389\/fpubh.2023.1244450","volume":"11","author":"AU Rehman","year":"2023","unstructured":"Rehman, A. U. et al. The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: A systematic review and meta-analysis. Front. Public. Health 11, 1244450. https:\/\/doi.org\/10.3389\/fpubh.2023.1244450 (2023).","journal-title":"Front. Public. Health"},{"key":"22780_CR17","doi-asserted-by":"publisher","unstructured":"Huangfu, P., Ugarte-Gil, C., Golub, J., Pearson, F. & Critchley, J. The effects of diabetes on tuberculosis treatment outcomes: An updated systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 23(7), 783\u2013796. https:\/\/doi.org\/10.5588\/ijtld.18.0433 (2019).","DOI":"10.5588\/ijtld.18.0433"},{"issue":"1","key":"22780_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2249.2005.02677.x","volume":"139","author":"S Yamashiro","year":"2005","unstructured":"Yamashiro, S. et al. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin. Exp. Immunol. 139(1), 57\u201364. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02677.x (2005).","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"22780_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/590565","volume":"47","author":"BI Restrepo","year":"2008","unstructured":"Restrepo, B. I. et al. Tuberculosis in poorly controlled type 2 diabetes: Altered cytokine expression in peripheral white blood cells. Clin. Infect. Dis. 47(5), 634\u2013641. https:\/\/doi.org\/10.1086\/590565 (2008).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"22780_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.ajpath.2013.12.015","volume":"184","author":"BK Podell","year":"2014","unstructured":"Podell, B. K. et al. Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: A model of diabetes-tuberculosis comorbidity. Am. J. Pathol. 184(4), 1104\u20131118 (2014).","journal-title":"Am. J. Pathol."},{"issue":"2","key":"22780_CR21","first-page":"144","volume":"42","author":"V Mahishale","year":"2017","unstructured":"Mahishale, V. et al. Effect of poor glycemic control in newly diagnosed patients with smear-positive pulmonary tuberculosis and type-2 diabetes mellitus. Iran. J. Med. Sci. 42(2), 144\u2013151 (2017).","journal-title":"Iran. J. Med. Sci."},{"key":"22780_CR22","doi-asserted-by":"publisher","first-page":"1207284","DOI":"10.3389\/fpubh.2023.1207284","volume":"11","author":"YJ Jeong","year":"2023","unstructured":"Jeong, Y. J. et al. Deaths from tuberculosis: Differences between tuberculosis-related and non-tuberculosis-related deaths. Front. Public. Health. 11, 1207284. https:\/\/doi.org\/10.3389\/fpubh.2023.1207284 (2023).","journal-title":"Front. Public. Health"},{"issue":"4","key":"22780_CR23","doi-asserted-by":"publisher","first-page":"e19399","DOI":"10.1371\/journal.pone.0019399","volume":"6","author":"CH Liu","year":"2011","unstructured":"Liu, C. H. et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: A 13-year experience. PLoS One 6(4), e19399. https:\/\/doi.org\/10.1371\/journal.pone.0019399 (2011).","journal-title":"PLoS One"},{"key":"22780_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijid.2021.06.062","volume":"109","author":"AB Seegert","year":"2021","unstructured":"Seegert, A. B. et al. Hypertension is associated with increased mortality in patients with tuberculosis in Guinea-Bissau. Int. J. Infect. Dis. 109, 123\u2013128 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"22780_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12879-019-4063-7","volume":"19","author":"R Aljadani","year":"2019","unstructured":"Aljadani, R., Ahmed, A. E. & Al-Jahdali, H. Tuberculosis mortality and associated factors at King Abdulaziz medical City hospital. BMC Infect. Dis. 19(1), 427. https:\/\/doi.org\/10.1186\/s12879-019-4063-7 (2019).","journal-title":"BMC Infect. Dis."},{"issue":"7","key":"22780_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","volume":"21","author":"KE Dooley","year":"2021","unstructured":"Dooley, K. E. et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: A phase 2, open-label, randomised, controlled trial. Lancet Infect. Dis. 21(7), 975\u2013983. https:\/\/doi.org\/10.1016\/S1473-3099(20)30770-2 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"22780_CR27","doi-asserted-by":"publisher","unstructured":"Putra, O. N., Yulistiani, Y. & Soedarsono, S. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis. Int. J. Mycobacteriol. 11(4), 349\u2013355. https:\/\/doi.org\/10.4103\/ijmy.ijmy_178_22 (2022).","DOI":"10.4103\/ijmy.ijmy_178_22"},{"key":"22780_CR28","doi-asserted-by":"publisher","unstructured":"Thomas, L. et al. Potential drug-drug interactions among hospitalised TB patients. Int. J. Tuberc. Lung. Dis. 26(12), 1137\u20131143. https:\/\/doi.org\/10.5588\/ijtld.22.0107 (2022).","DOI":"10.5588\/ijtld.22.0107"},{"key":"22780_CR29","doi-asserted-by":"publisher","unstructured":"Sun, H. J. et al. Analysis on adverse treatment outcome of rifampicin-resistant tuberculosis patients and influencing factors in 9 provinces in China, 2017\u20132021. Zhonghua Liu Xing Bing Xue Za Zhi 46(2), 188\u2013195. https:\/\/doi.org\/10.3760\/cma.j.cn112338-20240702-00394 (2025).","DOI":"10.3760\/cma.j.cn112338-20240702-00394"},{"key":"22780_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.meegid.2018.02.021","volume":"61","author":"M Zhang","year":"2018","unstructured":"Zhang, M. et al. Variants of TLR1 associated with tuberculosis susceptibility in the Chinese Tibetan population but not in Han Chinese. Infect. Genet. Evol. 61, 53\u201359 (2018).","journal-title":"Infect. Genet. Evol."},{"issue":"1","key":"22780_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/antibiotics12010166","volume":"12","author":"N Monde","year":"2023","unstructured":"Monde, N. et al. First and second-line anti-tuberculosis drug-resistance patterns in pulmonary tuberculosis patients in Zambia. Antibiot. (Basel) 12(1), 166. https:\/\/doi.org\/10.3390\/antibiotics12010166 (2023).","journal-title":"Antibiot. (Basel)"},{"issue":"1","key":"22780_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5588\/pha.22.0047","volume":"13","author":"J Izudi","year":"2023","unstructured":"Izudi, J., Bajunirwe, F. & Cattamanchi, A. Increase in rifampicin resistance among people previously treated for TB. Public. Health Action. 13(1), 4\u20136. https:\/\/doi.org\/10.5588\/pha.22.0047 (2023).","journal-title":"Public. Health Action"},{"issue":"6","key":"22780_CR33","doi-asserted-by":"publisher","first-page":"e044349","DOI":"10.1136\/bmjopen-2020-044349","volume":"11","author":"NN Tao","year":"2021","unstructured":"Tao, N. N. et al. Risk factors for drug-resistant tuberculosis, the association between comorbidity status and drug-resistant patterns: A retrospective study of previously treated pulmonary tuberculosis in Shandong, China, during 2004\u20132019. BMJ Open. 11(6), e044349. https:\/\/doi.org\/10.1136\/bmjopen-2020-044349 (2021).","journal-title":"BMJ Open."},{"issue":"9","key":"22780_CR34","doi-asserted-by":"publisher","first-page":"e0257647","DOI":"10.1371\/journal.pone.0257647","volume":"16","author":"N Gopalan","year":"2021","unstructured":"Gopalan, N. et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. PLoS One 16(9), e0257647. https:\/\/doi.org\/10.1371\/journal.pone.0257647 (2021).","journal-title":"PLoS One"},{"key":"22780_CR35","doi-asserted-by":"publisher","unstructured":"Collaborative Group for the Meta- et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet 392(10150), 821\u2013834. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1 (2018).","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"22780_CR36","doi-asserted-by":"publisher","unstructured":"Kang, Y. et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: Comparison of pre- and post-public-private mix periods. Tuberc Respir Dis. (Seoul) 84(1), 74\u201383. https:\/\/doi.org\/10.4046\/trd.2020.0093 (2021).","DOI":"10.4046\/trd.2020.0093"},{"issue":"4","key":"22780_CR37","doi-asserted-by":"publisher","first-page":"ofz118","DOI":"10.1093\/ofid\/ofz118","volume":"6","author":"EH Lee","year":"2019","unstructured":"Lee, E. H. et al. Improved fluoroquinolone-resistant and extensively drug-resistant tuberculosis treatment outcomes. Open. Forum Infect. Dis. 6(4), ofz118. https:\/\/doi.org\/10.1093\/ofid\/ofz118 (2019).","journal-title":"Open. Forum Infect. Dis."},{"key":"22780_CR38","doi-asserted-by":"publisher","unstructured":"Putra, O. N., Yulistiani, Y., Soedarsono, S. & Subay, S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Int. J. Mycobacteriol. 12(10), 1\u20139 https:\/\/doi.org\/10.4103\/ijmy.ijmy_217_22 (2023).","DOI":"10.4103\/ijmy.ijmy_217_22"},{"issue":"07","key":"22780_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.19982\/j.issn.1000-6621.20240088","volume":"46","author":"ZT Ye","year":"2024","unstructured":"Ye, Z. T. et al. Analysis of influencing factors of treatment outcomes of retreated multidrug-resistant\/rifampicin resistant pulmonary tuberculosis patients: A national multicenter retrospective cohortstudy. Chin. J. Antituberc. 46(07), 778\u2013784. https:\/\/doi.org\/10.19982\/j.issn.1000-6621.20240088 (2024).","journal-title":"Chin. J. Antituberc"},{"issue":"1","key":"22780_CR40","doi-asserted-by":"publisher","first-page":"21302","DOI":"10.1038\/s41598-025-06080-z","volume":"15","author":"Q Chen","year":"2025","unstructured":"Chen, Q. et al. Treatment outcomes in cavitary multidrug-resistant\/rifampicin-resistant tuberculosis and risk factors for cavity closure: a retrospective cohort study in Southwest China. Sci. Rep. 15(1), 21302. https:\/\/doi.org\/10.1038\/s41598-025-06080-z (2025).","journal-title":"Sci. Rep."},{"issue":"4","key":"22780_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cmi.2020.06.004","volume":"27","author":"M Gao","year":"2021","unstructured":"Gao, M. et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: A multicentre study. Clin. Microbiol. Infect. 27(4), 597\u2013602. https:\/\/doi.org\/10.1016\/j.cmi.2020.06.004 (2021).","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"22780_CR42","doi-asserted-by":"publisher","first-page":"e062857","DOI":"10.1136\/bmjopen-2022-062857","volume":"12","author":"V Panford","year":"2022","unstructured":"Panford, V. et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: A retrospective, cross-sectional study. BMJ Open. 12(7), e062857. https:\/\/doi.org\/10.1136\/bmjopen-2022-062857 (2022).","journal-title":"BMJ Open."},{"issue":"12","key":"22780_CR43","doi-asserted-by":"publisher","first-page":"e0260669","DOI":"10.1371\/journal.pone.0260669","volume":"16","author":"PW Wekunda","year":"2021","unstructured":"Wekunda, P. W., Aduda, D. S. O. & Guyah, B. Determinants of tuberculosis treatment interruption among patients in Vihiga county, Kenya. PLoS One. 16(12), e0260669. https:\/\/doi.org\/10.1371\/journal.pone.0260669 (2021).","journal-title":"PLoS One"},{"key":"22780_CR44","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1186\/1471-2458-11-696","volume":"11","author":"BN Muture","year":"2011","unstructured":"Muture, B. N. et al. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: A case control study. BMC Public. Health 11, 696. https:\/\/doi.org\/10.1186\/1471-2458-11-696 (2011).","journal-title":"BMC Public. Health"},{"key":"22780_CR45","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2147\/PPA.S219920","volume":"13","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Drug non-adherence and reasons among multidrug-resistant tuberculosis patients in Guizhou, China: A cross-sectional study. Patient Prefer Adherence 13, 1641\u20131653 (2019).","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"22780_CR46","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/infdis\/jiy675","volume":"219","author":"P Sinha","year":"2019","unstructured":"Sinha, P. et al. Undernutrition and tuberculosis: Public health implications. J. Infect. Dis. 219(9), 1356\u20131363. https:\/\/doi.org\/10.1093\/infdis\/jiy675 (2019).","journal-title":"J. Infect. Dis."},{"key":"22780_CR47","doi-asserted-by":"publisher","unstructured":"Haidar, A. & Horwich, T. Obesity cardiorespiratory fitness, and cardiovascular disease. Curr. Cardiol. Rep. 25(11), 1565\u20131571. https:\/\/doi.org\/10.1007\/s11886-023-01975-7 (2023).","DOI":"10.1007\/s11886-023-01975-7"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22780-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22780-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:49:12Z","timestamp":1762350552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22780-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22780"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22780-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Public Health Clinical Center of Chengdu as the lead center (Approval No. YJ-K2022-81-01). As a retrospective study using anonymized patient data, the requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"38801"}}